Resonance Health Akcija

Resonance Health EBITDA

Resonance Health (RHT.AX) EBITDA (Pelnas prieš palūkanas, mokesčius, amortizaciją ir susidėvėjimą) 2026-08-18 dieną yra −875 300,00 AUD. Praėjusiais metais EBITDA (Pelnas prieš palūkanas, mokesčius, amortizaciją ir susidėvėjimą) buvo −167 300,00 AUD — pokytis 423,19% (mažesnis).

EBITDA

−875 300,00AUD

YoY

423,19%

Paskutinį kartą atnaujinta:

Resonance Health EBITDA (Pelnas prieš palūkanas, mokesčius, amortizaciją ir susidėvėjimą) yra 2026 −875 300,00 AUD. Resonance Health EBITDA (Pelnas prieš palūkanas, mokesčius, amortizaciją ir susidėvėjimą) buvo 2025 −167 300,00 AUD. Tai sumažėjo 423,19% mažesnis lyginant su praėjusiais metais.
Access this data via the Eulerpool API

Resonance Health Akcijų analizė

Ką veikia Resonance Health? Resonance Health Ltd is an Australian company that operates in the medical technology industry. The company's business model is to offer groundbreaking solutions for the diagnosis and treatment of liver and iron diseases. As a pioneering company in the development of methods and technologies for quantifying liver and iron concentrations, Resonance Health continually sets new standards in the industry. The company was founded in 2000 by a team of biomedicine professionals from the University of Western Australia. Over the years, the company has gained a lot of experience and constantly evolved to keep up with the progress of medical technology. The goal is to provide patients with better treatment and improved quality of life. One division of the company is the development and manufacturing of diagnostic tools for quantifying liver and iron diseases such as hepatitis, fatty liver, or hemochromatosis. The quantification method used by Resonance Health is called FerriScan. This method is non-invasive and painless, using magnetic resonance imaging (MRI) to measure the concentration of iron in the tissue. This is particularly important as a change in iron content can indicate a progressing liver disease. In addition to the FerriScan diagnostic tool, Resonance Health also offers a software package for analyzing FerriScan results, which is used by physicians and clinicians to assess disease progression. Furthermore, the company also develops solutions in the field of hemochromatosis, a genetic disorder that can lead to increased iron levels in the body. Another division of Resonance Health is the provision of research and development services to further develop and improve FerriScan and other technologies. The company collaborates with other companies, scientific institutions, and universities to advance the current developments in liver and iron diagnostics. Resonance Health has a range of products that contribute to better diagnosis and treatment of liver and iron diseases. These include FerriScan, the FerriSmart software package for precise monitoring of iron and liver health, and Hepatica, a software supporting hospitals and clinics in the diagnosis of liver diseases. The company is an innovative leader in the industry, contributing to improving the quality of life for patients. The products and services of Resonance Health have helped doctors and clinicians to effectively treat and diagnose liver and iron diseases. Additionally, the company has established a strong scientific foundation and works closely with leading institutions to continuously develop innovative solutions. Resonance Health is a company with a rich history that continues to evolve to meet the demands of the medical technology industry. The company aims to continuously improve the diagnosis and treatment of liver and iron diseases and offer better solutions. Resonance Health yra viena populiariausių kompanijų Eulerpool.com.

Dažniausiai užduodami klausimai apie Resonance Health akciją

Resonance Health EBITDA (Pelnas prieš palūkanas, mokesčius, amortizaciją ir susidėvėjimą) 2026 m. yra −875 300,00 AUD.

Resonance Health EBITDA (Pelnas prieš palūkanas, mokesčius, amortizaciją ir susidėvėjimą) pasikeitė nuo −167 300,00 AUD iki −875 300,00 AUD, tai atitinka 423,19% pokytį. Reikšmė yra mažesnis nei praėjusiais metais.

Eulerpool rasite visą EBITDA (Pelnas prieš palūkanas, mokesčius, amortizaciją ir susidėvėjimą) Resonance Health istorinę raidą nuo 2006 m. – su metinėmis reikšmėmis, grafikais ir išsamiomis analizėmis.

EBITDA matuoja veiklos efektyvumą iki finansinės struktūros, mokesčių ir nesusigrąžintų amortizacijos išlaidos įtakos.

EBITDA = EBIT + Amortizacija ir susidėvėjimas

EBITDA (Pelnas prieš palūkanas, mokesčius, amortizaciją ir susidėvėjimą) AUD yra svarbus investuotojams veiksnys. Šios rodiklio pokyčiai gali signalizuoti apie pagerintas ar pablogėjusias finansines sąlygas, tiesiogiai paveikdami akcijos kainą. Eulerpool platformoje galite sekti EBITDA (Pelnas prieš palūkanas, mokesčius, amortizaciją ir susidėvėjimą) Resonance Health istorinę raidą ir realią laiko informaciją.

Access this data via the Eulerpool API

Pelno ir nuostolių ataskaita — Resonance Health

Visi pagrindiniai rodikliai — Resonance Health